Andrea Park

10 hours ago | fiercepharma.com | Andrea Park

Argenx has signed on as an early partner to a newly launched initiative from media companies NBCUniversal Local and Digital Health Networks (DHN) that plans to offer healthcare marketing in the form of video and digital storytelling content.

1 day ago | fiercepharma.com | Andrea Park

After a long winter, the start of summer is ushering in some much-needed sunshine, warmer weather and, for a handful of biopharma companies, refreshed branding. In the last week, a trio of companies across the industry have unveiled either slightly tweaked or completely new names, including the drugmakers formerly known as Coherus BioSciences and ViGeneron, and certain businesses within Fujifilm’s life sci group.

2 days ago | fiercepharma.com | Andrea Park

Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo Nordisk for support. The ADA’s obesity division went live last June, with a mission of advocating for more equitable access to obesity treatments and greater awareness and education around the condition, all of which the association is hoping will help break down stigmas linked to obesity and enable people to get the care and support they need.

3 days ago | fiercepharma.com | Andrea Park

Pharmas looking to recruit younger workers should meet members of Generation Z where they’re at: namely, TikTok and Instagram, according to a new report from the Association of the British Pharmaceutical Industry (ABPI). The report was based on recent surveys of teenagers and young adults aged 16 to 25 and STEM teachers and academic career counselors in the U.K., plus a STEM-centric focus group of 14- to 25-year-olds.

3 days ago | fiercebiotech.com | Andrea Park

A new study, sponsored by AstraZeneca and presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this week, suggests that using the Guardant360 CDx test to spot early signs of therapy resistance in advanced breast cancer patients and inform a treatment change could slash the risk of disease progression or death by half.